Cardiovascular Disease

The Practical Cardiology™ Cardiovascular Disease clinical resource center hosts content related to a wide array of cardiovascular conditions. The leading cause of death in the United States, the term cardiovascular disease encompasses a multitude of conditions and this page serves as a hub for information to several of the most common conditions, including atherosclerotic cardiovascular disease, acute coronary syndromes, hypertension, and more.

Putting the Debate to Rest: Recognizing the Role of Sleep in Cardiovascular Health, with Gregory Weiss, MD

December 02, 2022

Gregory Weiss, MD, provides insight into his perspective on the evolving recognition of the role of sleep health in cardiovascular disease prevention.

Study Shows Proper Diet Could Reduce Cardiovascular Risk by 10% or More

November 30, 2022

Leveraging data from the DASH trial, investigators from Beth Israel Deaconess Medical Center provides insight into the impact of different dietary approaches on 10-year ASCVD risk score among patients within the trial.

Holding Back on Adding Salt to Food Linked to Reduced Cardiovascular Risk

November 29, 2022

An analysis of self-reported dietary information from UK Biobank participants is providing insight into the effects of reducing added salt to foods on cardiovascular disease risk among adults without a history cardiovascular disease.

Influenza Responsible for Nearly 300k Heart Disease Deaths Per Year Globally

November 19, 2022

An analysis of data from 2010-2019 collected from 10 countries suggests influenza activity is responsible for 299k ischemic heart disease deaths per year on a global level.

FDA Warns 7 Companies Over Illegal Claims of Cardiovascular Benefits from Supplements

November 18, 2022

Announced in a statement on November 17, the US FDA issued letters to 7 companies related to unsupported claims of supplements being able to cure, treat, mitigate or prevent cardiovascular disease or related conditions, such as atherosclerosis, stroke or heart failure, in violation of the Federal Food, Drug, and Cosmetic Act.

Subcutaneous ICD Could Reduce Lead-Related Complications By More than 90%

November 14, 2022

Data from the ATLAS trial indicate use of a subcutaneous ICD was associated with a 92% reduction in lead-related complications compared to TV-ICD without compromising the effectiveness of shocks, but investigators express caution over an increased incidence of inappropriate shocks with the S-ICD.

CDC-Led Report Suggests 5-10 Years of Progress Against Cardiovascular Disease Erased During COVID-19 Pandemic

October 31, 2022

An analysis of trends in cardiovascular disease-related mortality from the US CDC WONDER database provides new insight into the apparent increases in mortality from cardiovascular disease observed during 2020 relative to the decreases in rate seen from 2010-2019.

Cardiology Month in Review: October 2022

October 29, 2022

The October 2022 cardiology month in review features the top content from HFSA 2022, new data related to antithrombotic therapy in atrial fibrillation, and shining a spotlight on the AHA’s scientific statement on patient-reported outcomes in peripheral artery disease.

Understanding Aficamten and the SEQUOIA-HCM Design, with Martin Maron, MD

October 05, 2022

Martin Maron, MD, sits down to discuss aficamten, the SEQUOIA-HCM trial, and the most pressing unmet needs in the management of hypertrophic cardiomyopathy.

Aficamten Could Improve Quality of Life, Symptom Burden in Hypertrophic Cardiomyopathy

October 02, 2022

Data presented at HFSA 2022 examining aficamten provides insight into the effects of the agent on LVOT-G, NYHA class, and KCCQ-OSS among patients with hypertrophic cardiomyopathy from the open-label extension trial.